Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY)...

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR)